Literature DB >> 27321025

PET-Based Personalized Management in Clinical Oncology: An Unavoidable Path for the Foreseeable Future.

Sandip Basu1, Abass Alavi2.   

Abstract

It is imperative that the thrust of clinical practice in the ensuing years would be to develop personalized management model for various disorders. PET-computed tomography (PET-CT) based molecular functional imaging has been increasingly utilized for assessment of tumor and other nonmalignant disorders and has the ability to explore disease phenotype on an individual basis and address critical clinical decision making questions related to practice of personalized medicine. Hence, it is essential to make a concerted systematic effort to explore and define the appropriate place of PET-CT in personalized clinical practice in each of malignancies, which would strengthen the concept further. The potential advantages of PET based disease management can be classified into broad categories: (1) Traditional: which includes assessment of disease extent such as initial disease staging and restaging, treatment response evaluation particularly early in the course and thus PET-CT response adaptive decision for continuing the same regimen or switching to salvage schedules; there has been continuous addition of newer application of PET based disease restaging in oncological parlance (eg, Richter transformation); (2) Recent and emerging developments: this includes exploring tumor biology with FDG and non-FDG PET tracers. The potential of multitracer PET imaging (particularly new and novel tracers, eg, 68Ga-DOTA-TOC/NOC/TATE in NET, 68Ga-PSMA and 18F-fluorocholine in prostate carcinoma, 18F-fluoroestradiol in breast carcinoma) has provided a scientific basis to stratify and select appropriate targeted therapies (both radionuclide and nonradionuclide treatment), a major boost for individualized disease management in clinical oncology. Integrating the molecular level information obtained from PET with structural imaging further individualizing treatment plan in radiation oncology, precision of interventions and biopsies of a particular lesion and forecasting disease prognosis.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Head-neck cancer; Lymphoma; Oncology; PET-CT; Personalized medicine; Precision medicine

Mesh:

Year:  2016        PMID: 27321025     DOI: 10.1016/j.cpet.2016.03.002

Source DB:  PubMed          Journal:  PET Clin        ISSN: 1556-8598


  14 in total

1.  Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.

Authors:  Manasa Ravindra; Mike R Wilson; Nian Tong; Carrie O'Connor; Mohammad Karim; Lisa Polin; Adrianne Wallace-Povirk; Kathryn White; Juiwanna Kushner; Zhanjun Hou; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2018-04-27       Impact factor: 7.446

2.  Effect of blood glucose level on standardized uptake value (SUV) in 18F- FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements.

Authors:  Mahsa Eskian; Abass Alavi; MirHojjat Khorasanizadeh; Benjamin L Viglianti; Hans Jacobsson; Tara D Barwick; Alipasha Meysamie; Sun K Yi; Shingo Iwano; Bohdan Bybel; Federico Caobelli; Filippo Lococo; Joaquim Gea; Antonio Sancho-Muñoz; Jukka Schildt; Ebru Tatcı; Constantin Lapa; Georgia Keramida; Michael Peters; Raef R Boktor; Joemon John; Alexander G Pitman; Tomasz Mazurek; Nima Rezaei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-22       Impact factor: 9.236

Review 3.  PET imaging of recurrent and metastatic prostate cancer with novel tracers.

Authors:  Francesca V Mertan; Liza Lindenberg; Peter L Choyke; Baris Turkbey
Journal:  Future Oncol       Date:  2016-08-16       Impact factor: 3.404

Review 4.  PET/MR: Yet another Tesla?

Authors:  Markus Schwaiger; Karl Kunze; Christoph Rischpler; Stephan G Nekolla
Journal:  J Nucl Cardiol       Date:  2016-09-22       Impact factor: 5.952

5.  An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy.

Authors:  Majid Assadi; Reza Nemati; Hossein Shooli; Seyed Javad Rekabpour; Iraj Nabipour; Esmail Jafari; Ali Gholamrezanezhad; Abdullatif Amini; Hojjat Ahmadzadehfar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-18       Impact factor: 9.236

6.  CD38 as a PET Imaging Target in Lung Cancer.

Authors:  Emily B Ehlerding; Christopher G England; Dawei Jiang; Stephen A Graves; Lei Kang; Saige Lacognata; Todd E Barnhart; Weibo Cai
Journal:  Mol Pharm       Date:  2017-06-08       Impact factor: 4.939

7.  Let's embrace optical imaging: a growing branch on the clinical molecular imaging tree.

Authors:  Milou E Noltes; Gooitzen M van Dam; Wouter B Nagengast; Pieter J van der Zaag; Riemer H J A Slart; Wiktor Szymanski; Schelto Kruijff; Rudi A J O Dierckx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-12       Impact factor: 9.236

8.  The Landscape of Clinical Trials Evaluating the Theranostic Role of PET Imaging in Oncology: Insights from an Analysis of ClinicalTrials.gov Database.

Authors:  Yu-Pei Chen; Jia-Wei Lv; Xu Liu; Yuan Zhang; Ying Guo; Ai-Hua Lin; Ying Sun; Yan-Ping Mao; Jun Ma
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

Review 9.  Radiolabeled theranostics: magnetic and gold nanoparticles.

Authors:  Saeideh Same; Ayuob Aghanejad; Sattar Akbari Nakhjavani; Jaleh Barar; Yadollah Omidi
Journal:  Bioimpacts       Date:  2016-09-30

Review 10.  Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.

Authors:  S Lheureux; C Denoyelle; P S Ohashi; J S De Bono; F M Mottaghy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-10       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.